Qaiser Bashir

I put together a free guide on using AI the right way in medicine. How to use it as a teacher. Where the ethical line is. 45+ research databases. Formal AI courses from AMA, AAMC, Harvard, Stanford. For medical students, IMGs, residents, and fellows: linkedin.com/posts/faiz-anw…

The advent of AI might be just the latest stage in a guiding biological process that has produced ever more complex, mutually dependent organisms over the history of life go.nature.com/4rjN8Wf

HLA vaccine effect in double cord blood transplant: a Chinese cohort ow.ly/PZuX50XjkuY #transplantation

Booth and colleagues report long-term safety and efficacy data from 62 patients with adenosine deaminase deficiency treated with autologous hematopoietic stem cells transduced with a lentiviral vector containing ADA. Full study results: nej.md/4hignEA

Please share this!!! @ASTCT @DrMarcosdelima @doctorpemm @NitinJainMD @Transplant_Doc @DQBMD

Comments LLMs show promise but not ready for autonomous clinical use Action tasks = main bottleneck MedAgentBench is publicly available → a framework to push safe progress

Results Claude 3.5 Sonnet → Best (69.7% SR; 85% query, 54% action) GPT-4o → 64% Open-weight models lagged Most models stronger at retrieval than at actions

MedAgentBench: A Virtual EHR Environment to Benchmark Medical LLM Agents | NEJM AI ai.nejm.org/doi/full/10.10…

a virtual twin model to simulate patient-specific response, toxicity, and resistance to CAR T-cell therapy in relapsed/refractory myeloma.

Virtual twins for personalised CAR T-cell therapy in myeloma - The Lancet Haematology thelancet.com/journals/lanha…

@HindRafei @MDAndersonNews Congratulations _ so well deserved 👏👏

Thrilled, honored, and humbled to be selected as a new Sabin fellow @MDAndersonNews! Immensely grateful to the Sabin family for their generous support and inspiring vision to advance innovative cancer research and therapies. Congratulations to all the new fellows— excited for the impactful journey ahead! 🙏🏻

FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma fda.gov/drugs/resource… @FDAOncology

ICYMI: FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma sohoinsider.com/news/fda-panel…

I’m impressed by the 100% ORR in dual-antigen–naïve RRMM pts—JNJ-5322 could rival CAR-Ts without the wait. That said, durability is still a question, and 28% gr 3/4 infection rate isn’t trivial. Promising, but needs longer follow-up. #ASH2025 #MM

Phase 1 (NCT05652335) enrolled RRMM 126 pts (36 at RP2D 100 mg Q4W; median 4 prior lines; all triple-class exposed: At RP2D: • ORR = 100% in dual-antigen–naïve pts (n=27) • ORR = 86% overall (n=36) • CRS = 59% (all gr 1–2), ICANS rare (2%, all gr 1) • Infections gr 3/4 = 28%

#asco2025 Update: JNJ-5322 is a next-gen T-cell redirecting bispecific antibody targeting BCMA + GPRC5D with low-affinity CD3 for improved safety. SubQ dosing Q2W or Q4W. Step-up dose (5 mg) used to reduce CRS risk. #MultipleMyeloma #Immunotherapy meetings.asco.org/abstracts-pres…